Biomedical subjects

U Langel

Publications and source records attributed to U Langel.

At least 73 records · Page 4Linked to original sources

PubMed1997

Galparan: a powerful insulin-releasing chimeric peptide acting at a novel site.

Galparan is a 27-amino acid long chimeric peptide, GWTLNSAGYLLGP-INLKALAALAKKIL amide, consisting of galanin-(1-13) linked to mastoparan amide via a peptide bond to provide the mastoparan and galanin effector parts of the molecules. Galparan (10 microM) powerfully stimulates insulin secretion from isolated rat pancreatic islets in a reversible and dose-dependent manner; the stimulation is 26-fold at 3.3 mM glucose and 6-fold at 16.7 mM glucose. Galparan also enhances insulin secretion to a similar extent from islets of diabetic GK rats. The stimulatory effect of galparan on insulin release is not directly dependent on extracellular Ca2+, nor can it be explained only by changes in free cytosolic Ca2+ concentrations. Furthermore, galparan is effective in evoking insulin release in B cells depolarized by 25 mM KCl when ATP-sensitive K+ channels are kept open by diazoxide. Thus, galparan, like mastoparan, stimulates exocytosis of insulin at a distal site in the stimulus-secretion coupling of the B cell. This distal site is not identical to that used by mastoparan, as pertussis toxin pretreatment does not influence the insulinogenic effect of galparan. In conclusion, galparan evokes a large and reversible insulin secretion, acting at a yet unknown distal site and also promoting exocytosis in depolarized B cells from normal rats as well as diabetic GK rats.

Amino Acid Sequence↗

PubMed1997

Attempt to solubilize Na+/K+-exchanging ATPase with amphiphilic peptide PD1.

The effect of the 24-amino-acid-long peptide, PD(1), on rat cerebral cortical Na+/K+ -exchanging ATPase (EC 3.6.1.37) has been studied. Incubation of the enzyme preparation (25 degrees C for 10-25 min) with the peptide (10(-7) - 10(-4) M) did not appreciably affect the activity of the enzyme, only 5-8% activation being registered. On the other hand, PD(1) completely eliminated the cooperative nature of Na+ -binding to Na+/K+ -exchanging ATPase (n(H) decreased from 1.4 to 0.9) and slightly (1.2-fold) decreased the affinity for Na+. ATP, a substrate of activity for Na+/K+ -exchanging ATPase, blocked the PD(1)-promoted effect on the cooperativity for Na+. Incubation of cerebral cortical membranes with 5 x 10(-4) M PD(1) revealed a shift (from 19.5 degrees C to 21.4 degrees C) of the typical break on the Arrhenius plot (15-37 degrees C). Prolonged incubation of enzyme preparation (25 degrees C for 1-2 h) with PD(1) (4.5 x 10(-4) - 0.7 x 10(-2) M) followed by centrifugation of the mixture at 53,000 g for 90 min, resulted in loss of the activity both in the supernatant and the sediment, while the protein content in the supernatant and the sediment remained unchanged. After a short incubation (25 degrees for 10 min) with PD(1) (1 x 10(-6) M), followed by centrifugation, the full activity of Na+/K+ -exchanging ATPase in the sediment was restored. These data suggest that peptitergent PD(1) does not solubilize the transmembrane protein Na+/K+ -exchanging ATPase, although it abolishes the cooperative effect of Na+.

Animals↗

PubMed1996

Pituitary adenylate cyclase activating polypeptide (PACAP) redistributes the blood within the pancreas of anesthetized rats.

The aim of the study was to evaluate the effects of pituitary adenylate cyclase activating polypeptide-38 (PACAP-38) on splanchnic blood flow in anesthetized rats. For this purpose, either PACAP-38 dissolved in saline or saline alone was injected intravenously 5 (10 nmol/kg body weight (bw) PACAP-38) and 30 min (5 or 10 nmol/kg) before measurements. The blood flow to the whole pancreas, islets, duodenum and colon was then measured with a microsphere technique. The higher dose of PACAP-38 slightly increased blood glucose concentrations at both 5 and 30 min after administration, whereas the lower had no effect. Both doses of PACAP-38 induced a transient initial decrease in mean arterial blood pressure. The lower dose of PACAP-38 decreased fractional islet blood flow 30 min after administration, but did not affect the other blood flows. The higher dose of the peptide (10 nmol/kg bw) caused an increase in whole pancreatic blood flow at both 5 and 30 min after administration, whereas islet blood flow was only increased at the former time. At both time points PACAP-38 redistributed the blood flow within the pancreas in favour of the exocrine pancreas. This resulted in a decreased fractional islet blood flow, i.e., the fraction of whole pancreatic blood flow diverted through the islets. At 5 min after PACAP-38 administration duodenal blood flow was decreased, whereas after 30 min no effects on duodenal or colonic blood flow were observed. Administration of a VIP antagonist intravenously (20 nmol/kg bw) decreased the PACAP-38-induced pancreatic blood flow increase and intrapancreatic redistribution. When only the VIP antagonist was given both pancreatic and islet blood decreased in concert. It is concluded that administration of PACAP-38 induces a blood flow increase in the pancreas, preferably in the exocrine parts of the gland, by actions mediated by PACAP-38 receptors shared with VIP.

Amino Acid Sequence↗

PubMed1996

Ligand binding and functional effects of systematic double D-amino acid residue substituted neuropeptide Y analogs on Y1 and Y2 receptor types.

In order to identify the signal epitopes of the neuropeptide Y (NPY) molecule, the conformation of the NPY molecule was pertubated by a systematic double D-amino acid replacement of neighbouring residues. These NPY-analogs were examined for receptor affinity and on biological activity. The rat cerebral cortex and hippocampus were used for binding characteristics on Y1 and Y2 binding sites, respectively, while the isolated guinea pig caval vein and rat vas deferens were used in functional characterization of Y1 and Y2 receptors, respectively. The NPY analogs were examined as ligands at [3H]NPY binding sites in homogenates of the rat brain. Pairwise D-substitutions of either of the first 6 amino acid residues in the N-terminal part of the molecule resulted in a 20-100-fold loss of affinity for Y1 binding sites compared with the native peptide. In comparison, the same analogs displayed affinities, which were about 8-40 times lower than NPY itself at Y2 binding sites. Especially [D-Ser3,D-Lys4]NPY had a low affinity to Y1 and Y2 binding sites. For many of the pairwise D-amino acid substituted NPY analogs, there were similar affinities for Y1 and Y2 binding sites in the cerebral cortex and hippocampus, respectively. D-Amino acid residue substitutions in positions 7 and 8 did essentially not affect the affinity to either type of binding site, while such replacements in positions 19 and 20 resulted in a drastic loss of affinity to both types of NPY binding site. In contrast, [D-Tyr21,D-Ser22]NPY was only slightly less potent than NPY itself on either type of binding site. Pairwise D-amino acid substitutions in the C-terminal (positions 27 to 36) decreased the affinity to Y1 and Y2 binding sites by 2 to 3 orders of magnitude. In the guinea pig vena cava the D-amino acid substituted NPY analogs evoked a concentration-dependent contraction with an rank order of potency similar to that of the respective analog at Y1 binding sites in the cerebral cortex. Similarly, in the rat vas deferens the D-amino acid substituted NPY analogs evoked a concentration-dependent inhibition of the electrically-stimulated twitches with a rank order of potency similar to that of the respective analog at Y2 binding sites in the hippocampus. However, D-amino acid replacements in positions 25 and 26 resulted in an analog which was virtually inactive in the vas deferens, but almost equipotent with NPY in the vena cava. In conclusion, the present study has shown that N-terminal double D-amino acid substitutions in the NPY molecule reduced the binding affinity to and activation more of the Y1 receptor, than of the Y2 receptor, while both receptors were quite sensitive to double D-amino acid changes in positions 19 and 20 and in the C-terminal end of the NPY molecule.

Amino Acids↗

PubMed1996

A galanin-mastoparan chimeric peptide activates the Na+,K(+)-ATPase and reverses its inhibition by ouabain.

The effect of the neuropeptide galanin, the wasp venom toxin amphiphilic peptide toxin mastoparan and the chimeric peptide, galparan, consisting of N-terminal 13 amino acids of neuropeptide galanin linked at C-terminus to mastoparan amide (and its inactive analog Mas17) on the activity of Na+,K(+)-ATPase has been studied. Mastoparan inhibits the activity of the Na+,K(+)-ATPase with IC50 = 7.5 microM and also reduces the cooperativity for Na+ and K+, respectively, while galanin has no effect on the Na+,K(+)-ATPase activity. The chimeric peptide, galanin(1-13)-mastoparan amide (galparan), exhibits biphasic interaction with Na+,K(+)-ATPase, it activates the enzyme at maximal stimulating concentration of 4 microM followed by inhibition of the enzyme with IC50 of 100 microM. At maximum stimulating concentration (4 microM), galparan partly reduces the cooperativity only for Na+ and it also counteracts the inhibitory effect of oubain on Na+,K(+)-ATPase. Galparan's stimulatory effect was influenced by ATP. The chimeric peptide [19Lys,26Leu]-galparan, containing the inactive analog of mastoparan (Mas17), has no effects on rat brain Na+,K(+)-ATPase activity. Both chimeric peptides galparan and [19Lys,26Leu]-galparan are high-affinity galanin receptor ligands with IC50 of 6.4 nM and 0.71 nM, respectively, while galanin (1-13) and mastoparan alone have significantly lower affinity for the galanin receptor, IC50 of 125 nM and 1 microM, respectively. The ability of chimeric peptides to bind to galanin receptors does not correlate with their effects on the Na+,K(+)-ATPase.

Amino Acid Sequence↗

PubMed1996

A study of melittin, motilin and galanin in reversed micellar environments, using circular dichroism spectroscopy.

Circular dichroism spectroscopy has been used to study the behaviour of the cytolytic peptide melittin, the intestinal peptide hormone motilin (porcine) and the neuropeptide galanin (porcine) in various reversed micellar systems. The micellar systems used contained sodium dodecyl sulphate, bis(2-ethylhexyl) sulfosuccinate, n-dodecyltrimethylammonium chloride or polyoxyethylene(7) lauryl ether. Various structural changes of the peptides, induced either by varying the water content or the surface charge of the reversed micelles, could be monitored. Melittin has in all micellar systems a large amount of alpha-helix, and is almost unaffected by both water content and the surface charge of the reversed micelles. Motilin on the other hand attains an alpha-helical structure at low water content only. The surface charges seem to be of importance for the association between motilin and the hydrated reversed micellar surface. Galanin has the most complicated behaviour with a large dependence on surface charge and with a water content dependence which varies with the surfactant used. Stabilization of alpha-helical secondary structures was only seen in negatively charged reversed micelles. These observations indicate a specific interaction between galanin and surfactant, probably of electrostatic nature.

Amino Acid Sequence↗

PubMed1995

Binding and agonist/antagonist actions of M35, galanin(1-13)-bradykinin(2-9)amide chimeric peptide, in Rin m 5F insulinoma cells.

The chimeric peptide M35 [galanin(1-13)-bradykinin(2-9) amide] is a high-affinity galanin receptor ligand acting as a galanin receptor antagonist in the rat spinal cord, rat hippocampus and isolated mouse pancreatic islets. We have radiolabelled M35 and performed equilibrium binding studies with [125I]M35 on the rat pancreatic beta-cell line Rin m 5F, whereby we show the existence of high-affinity binding site (KD = 0.9 +/- 0.1 nM) with a Bmax of 72 +/- 3 fmol/mg protein. Galanin displaces [125I]M35 with the same affinity (KD = 1 nM) as it displaces [125I]galanin. Displacement of [125I]galanin by M35 from Rin m 5F cell membranes shows the presence of two binding sites for M35 with KD-values of 0.3 +/- 0.1 nM and 0.52 +/- 0.03 microM, respectively. The GTP- and pertussis toxin-sensitivity of M35 binding to Rin m 5F membranes shows that binding of [125I]M35 is almost completely abolished by the presence of GTP or after pertussis toxin treatment of the cells, indicating an agonist-like binding of M35 to the galanin receptors. M35 has a dual effect on the galanin mediated inhibition of forskolin stimulated cyclic AMP production in Rin m 5F cells: at low concentrations M35 antagonises the effect of galanin, whereas at concentrations above 10 nM M35 acts as a galanin receptor agonist. These agonist-like effects of galanin and M35 are not additive, thus the mixed agonist/antagonist properties arise from the chimeric nature of M35[galanin(1-13)-bradykinin(2-9)amide] acting solely at galanin receptors.

Animals↗

PubMed1995

Solvent stabilized solution structures of galanin and galanin analogs, studied by circular dichroism spectroscopy.

Circular dichroism spectroscopy has been used to study how different solvents stabilize secondary structure in the neuropeptide galanin (rat), two N-terminal fragments of galanin, galanin(1-12) and galanin(1-16), and six other differently charged analogs. Among these analogs, the peptide M40, galanin(1-13)-Pro-Pro-Ala-Leu-Ala-Leu-Ala amide, is a high affinity, receptor subtype specific galanin receptor antagonist. The different solvents include sodium dodecyl sulfate (SDS) micelle solutions, 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-phosphoglycerol (DOPG) vesicle solutions. 100% 1,1,1,3,3,3-hexafluoro-2-propanol (HFP) and 100% 2,2,2-trifluoroethanol (TFE). DOPC vesicles did not change the structure of the peptides as compared to aqueous solvent. The negatively charged DOPG vesicles and SDS micelles induced similar changes towards alpha-helical structures in all peptides. The HFP and TFE solvents have an even stronger tendency to stabilize alpha-helical conformations in these peptides. Since DOPG vesicles can be considered as a model system for negatively charged biological membranes, the solution structures observed in the presence of DOPG or SDS may be the most relevant for the in vivo situation. Correlations between the binding affinity of the peptides to hippocampal galanin receptors and their observed structures in the DOPG solvent were investigated.

Amino Acid Sequence↗

PubMed1995

Differential regulation of adenylate cyclase activity in rat ventral and dorsal hippocampus by rat galanin.

Rat galanin inhibits basal as well as forskolin-stimulated adenylate cyclase activity in rat ventral and dorsal hippocampus. The inhibition of adenylate cyclase activity, both basal and forskolin-stimulated, is characterised by IC50 values being 250-fold lower in ventral hippocampus (IC50 = 1.1 nM) compared to the dorsal hippocampus (IC50 = 270 nM). The maximal inhibition of basal and forskolin-stimulated adenylate cyclase activity in both ventral and dorsal hippocampus in the presence of 10 microM rat galanin is 34-45%. The analysis of the binding data obtained with 125I-labelled Tyr26-porcine galanin as a tracer reveals similar binding constants for rat galanin in both ventral and dorsal hippocampus with 4.8-fold higher concentration of galanin receptors in the ventral hippocampus. Putative galanin receptor subtype differences between the ventral and dorsal hippocampus have been noted by Hedlund et al. (Eur. J. Pharmacol., 224 (1992) 203-205). This study yields further confirmation for the existence of different galanin receptor subtypes or for differential coupling of galanin receptors to the adenylate cyclase in the dorsal versus ventral hippohampus.

Adenylyl Cyclase Inhibitors↗

PubMed1995

Galanin--a neuropeptide with inhibitory actions.

1. Galanin is a 29 (in humans 30) amino acids long neuropeptide with mostly inhibitory, hyperpolarizing actions. 2. Differential structural requirements of truncated forms of galanin and differential agonist/antagonist behaviour of chimeric peptides, high affinity galanin receptor ligands suggest the presence of pharmacologically distinct galanin receptor subtypes. 3. The galanin receptor from human Bowes melanoma cell line--a member of G-protein coupled receptor superfamily--has been cloned. 4. Galanin acts via Gi/G(o) proteins inhibiting cAMP production, inositol phosphate turnover, opening K+ channels or closing Ca2+ channels.

Amino Acid Sequence↗

PubMed1995

Metabolism of galanin and galanin (1-16) in isolated cerebrospinal fluid and spinal cord membranes from rat.

The occurrence of galanin (GAL) in the spinal cord and reports suggesting that it acts as an endogenous inhibitory spinal modulator in sensory/noxious transmission, have focused interest on its metabolism in the spinal cord. The metabolic half-lives and degradation patterns of GAL(1-29) and the high affinity N-terminal fragment GAL(1-16), were determined in isolated cerebrospinal fluid (CSF) from rats, and analysed by reverse phase HPLC. The half-lives for GAL(1-29) and GAL(1-16) in isolated rat CSF at 37 degrees C were 120 min and 60 min, respectively. The first degradation products which we could isolate and identify of GAL(1-16) were: GAL(3-16) and GAL(3-12) and for GAL(1-29): GAL(1-5) and GAL(1-4), all without affinity to spinal galanin receptors. Degradation studies of GAL(1-29) and GAL(1-16) in a spinal cord membrane preparation, in absence or presence of different protease inhibitors: E-64, pepstatin A, 3,4-DCI, bestatin, phosphoramidon, kelatorphan and thiorphan, or metal chelators: EDTA, EGTA and o-phenanthrolin, suggest that a phosphoramidon sensitive zinc-metalloprotease is mainly responsible for the degradation of GAL(1-29) and GAL(1-16), since both o-phenanthrolin (0.3 mM) and phosphoramidon (920 microM) substantially prolong their half-lives.

Amino Acid Sequence↗

PubMed1995

Peripheral axotomy increases the expression of galanin message-associated peptide (GMAP) in dorsal root ganglion cells and alters the effects of intrathecal GMAP on the flexor reflex in the rat.

We have previously reported that galanin message-associated peptide (GMAP), a fragment of galanin precursor protein, occurs in a limited number of dorsal root ganglion (DRG) cells in rats with intact sciatic nerves. In the present study, the localization of GMAP in dorsal root ganglia, dorsal roots and dorsal horn was analyzed immunohistochemically and compared between rats with intact and sectioned sciatic nerves. Furthermore, the effects of intrathecal (i.t.) GMAP on the flexor reflex in rats with intact and sectioned nerves were examined. In rats with intact sciatic nerves, i.t. GMAP elicited a moderate facilitation of the flexor reflex. The facilitation of the flexor reflex induced by conditioning stimulation (CS) of cutaneous C-fibers was strongly blocked by GMAP. GMAP also selectively antagonized the reflex facilitatory effect of i.t. substance P (SP), but not i.t. vasoactive intestinal peptide (VIP). Unilateral sciatic nerve section induced an upregulation of GMAP in the ipsilateral dorsal root ganglia 2 weeks after axotomy. The effect of GMAP on the baseline reflex was similar in normal and axotomized rats, but the blocking effect of GMAP on C-fiber CS-induced facilitation was significantly reduced after axotomy. GMAP did not antagonize the reflex facilitatory effect of SP after axotomy, whereas an antagonism on VIP-induced facilitation was observed. The possible role of GMAP in spinal transmission and comparison with the effects of galanin are discussed.

Animals↗

PubMed1995

New high affinity peptide antagonists to the spinal galanin receptor.

1. The role of endogenous galanin in somatosensory processing has been studied with galanin receptor antagonists. The new galanin receptor ligands C7, M32, M38 and M40 bind with high affinity (Kd in nanomolar range) to spinal cord galanin receptors and possess oxidative stability as compared to earlier generations of peptide ligands. These peptides have been examined in the spinal flexor reflex model where exogenous galanin exhibited biphasic excitatory and inhibitory effects. 2. Intrathecal administration of C7 [galanin(1-13)-spantide] and M32 [galanin (1-13)-neuropeptide Y(25-36) amide] blocked facilitation of the nociceptive flexor reflex induced by 30 pmol intrathecal galanin in decerebrate, spinalized rats in a dose-dependent manner, thus behaving as antagonists of the galanin receptor. In contrast, M38[galanin(1-13)-(Ala-Leu)3-Ala amide] and M40 [galanin(1-13)-Pro-Pro-(Ala-Leu)2-Ala amide], exhibited only weak antagonism at high doses in this model. Moreover, lower doses of M40 potentiated galanin-induced reflex facilitation. C7 was neurotoxic at high doses in the rat spinal cord. 3. M32 and C7 were potent antagonists of galanin receptors in rat spinal cord, in correlation with their in vitro binding characteristics. In contrast, M38 and M40, despite their high in vitro affinity, exhibited only very weak antagonism. Moreover, M40 may also behave as a partial agonist. 4. Previous studies have shown that the galanin receptor may be heterogeneous. The discrepancy between in vitro binding and in vivo antagonistic potency of M38 and M40 may also suggest the presence of different galanin receptor subtypes within the rat spinal cord. However, other explanations for the discrepancy, such as differences in metabolic stability, diffusion rates and penetration to the site of action are also possible.

Amino Acid Sequence↗

PubMed1995

Synthesis of an N-methyldehydroalanine-containing fragment of microcystin by combination of solid phase peptide synthesis and beta-elimination in solution.

A new method for the synthesis of dehydroalanine (delta Ala)-containing peptides has been developed by combining solid phase peptide synthesis (tert-butyloxycarbonyl/HF-chemistry) with solution synthesis. A sequence from cyanobacterial hepatotoxin microcystin, Ac-D-gamma-Glu-[N-Me-delta Ala]-D-Ala-Leu amide was chosen as a model peptide. The precursor for the synthesis of the dehydroalanine-containing peptide, Ac-D-gamma-Glu-[N,S-diMeCys]-D-Ala-Leu, was synthesized on a solid phase followed by sulfonium salt formation on the resin. The resulting S,S-dimethylated peptide was cleaved from the resin with liquid HF. The HPLC-purified S,S-dimethylated cysteine-containing precursor peptide was subjected to beta-elimination in solution catalysed by DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) in methanol. The final product, Ac-D-gamma-Glu-[N-Me-delta Ala]-D-Ala-Leu amide, was purified by HPLC, and analysed by mass spectrometry and 1H NMR spectroscopy. The stability of the model peptide under acidic, neutral and basic conditions has been studied.

Alanine↗

PubMed1994

N-terminally elongated fragments of galanin(1-16) inhibit insulin secretion from isolated mouse islets.

The neuropeptide galanin inhibits insulin secretion and has been suggested to be an adrenergic co-transmitter in the endocrine pancreas. Recently, N-terminally elongated forms of galanin have been identified in both porcine brain and adrenals. Whether these elongated peptides show galanin-like biological effects is not known. We therefore synthesized two N-terminally elongated fragments of galanin(1-16), which contains the active site of galanin. The synthesized peptides were galanin(-9-16) and galanin(-7-16), which correspond to amino acids 24-61 and 26-61 in the galanin precursor molecule. Both these peptides were found to potently inhibit glucose-(11.1 mM)-stimulated insulin secretion from isolated mouse islets of Langerhans in all concentrations studied (1-1000 nM) (P < 0.0001). The potency of the peptides was not different from that of synthetic rat galanin. Thus, at 100 nM, insulin secretion was inhibited by galanin(-7-16) by 83 +/- 7% and by galanin(-9-16) by 71 +/- 17% and by rat galanin by 93 +/- 4% (not statistically different). Furthermore, the galanin receptor antagonist, M35 (10 nM), prevented the inhibitory action of the two N-terminally galanin fragments. This study thus shows that N-terminally elongated galanin-fragments as entire galanin inhibits insulin and thus indicates that the effect of galanin on insulin secretion is not dependent on a free amino-terminus.

Animals↗

PubMed1994

Biological activities of two endogenously occurring N-terminally extended forms of galanin in the rat spinal cord.

The occurrence of two N-terminally extended forms of galanin in the porcine adrenal medulla was reported earlier by Bersani et al. (1991). We have synthesized and examined the ability of these two extended forms of galanin, galanin-(-7-29) and galanin-(-9-29), to bind to galanin receptors in the rat dorsal spinal cord. The effect of intrathecal (i.t.) injection of these peptides on spinal flexor reflex excitability in decerebrate, spinalized, unanesthetized rats was also studied. Both galanin-(-7-29) and galanin-(-9-29) fully displaced specific 125I-monoido-[Tyr26]porcine galanin (125I-galanin) binding to membranes prepared from rat dorsal spinal cord, with IC50 values 0.13 and 0.14 microM, respectively. The metabolic half-lives in spinal cord membranes for galanin-(1-29), galanin-(-7-29) and galanin-(-9-29) were 117 +/- 17, 271 +/- 23 and 185 +/- 19 min, respectively. I.t. injection of galanin-(-7-29) and galanin-(-9-29) mimicked the biphasic facilitatory and inhibitory effect of i.t. galanin-(1-29) on flexor reflex excitability and antagonized C-fiber conditioning stimulus-induced spinal cord hyperexcitability, but with reduced potencies compared to galanin-(1-29). We suggest that the N-terminally extended forms of galanin act as endogenous ligands with low agonist activity.

Action Potentials↗

PubMed1994

Galanin message-associated polypeptide (GMAP) does not affect insulin secretion from isolated islets.

Galanin message-associated polypeptide (GMAP) is processed from preprogalanin. Recently, GMAP-like immunoreactivity was demonstrated in insulin cells in the endocrine pancreas. We therefore examined whether synthetic rat GMAP, like galanin, inhibits glucose-stimulated insulin secretion from isolated rat and mouse islets. We found, however, that over a wide dose range (0.1 nM to 1 microM) GMAP did not affect insulin secretion stimulated by 8.3 or 11.1 mM glucose during a 60-min incubation of single rat or mouse islets. In contrast, rat galanin, as expected, completely abolished glucose-stimulated insulin secretion at 100 nM. Thus, in contrast to galanin, GMAP does not affect insulin secretion in isolated rodent islets.

Amino Acid Sequence↗

PubMed1994

Comparison of the solution structures of the chimeric peptides galanin(1-12)-Ala-neuropeptide Y(25-36)amide and galanin(1-12)-Pro-neuropeptide Y(25-36)amide.

In a previous study [Arvidsson, K., Land, T., Langel, U., Bartfai, T. & Ehrenberg, A. (1993) Biochemistry 32, 7787-7798], the 25-amino-acid-residue chimeric peptide M32, galanin(1-12)-Pro-neuropeptide Y(25-36)amide, was found to bind very strongly to galanin receptors and also to have considerable affinity to neuropeptide Y receptors. The solution structure of M32 in 30% (by vol.) 1,1,1,3,3,3-hexafluoro-2-propanol, was determined from structural restraints obtained by two-dimensional 1H-NMR. Another peptide, M88, with Ala instead of Pro in position 13, was shown to bind with tenfold lower affinity to galanin receptors, i.e. with nearly the same affinity as galanin itself. The binding to neuropeptide Y receptors was altered in the opposite sense. The peptide M88 has now been examined by two-dimensional 1H-NMR under the same conditions as applied for M32. Using NMR-derived restraints, we have calculated structures of M88 by means of the programs CALIBA, HABAS and DIANA, and refined them by restrained energy minimisation and restrained molecular dynamics. The use of CALIBA and HABAS meant that the restraints were less restrictively formulated, than in the previous work. Hence, structures of M32 were recalculated in the same way as for M88, also including some additional restraints, possible to identify by comparison of the NMR spectra of the two peptides. The new structures of M32 confirm an alpha-helix starting at Pro13, but now continuing until Gln23, instead of ending at Ile20. Conversely, no secondary structure is now expressed in the N-terminal section. It is concluded that in the case of peptides the details of the calculated structures depend on how the restraints are calibrated. In M88, an alpha-helix is found over a long section, approximately Ser6-Gln23. Possible correlations between the binding affinities to receptors and the solution structures of the peptides M32 and M88 are discussed. This is done with particular reference to the length and stability of the alpha-helix and the flexibility of the N-terminal section and its bending direction versus the helix.

Amino Acid Sequence↗